157 related articles for article (PubMed ID: 17548040)
1. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
[TBL] [Abstract][Full Text] [Related]
2. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; van Eijck CH; Kam BL; van Essen M; Teunissen JJ; Krenning EP
Semin Nucl Med; 2010 Mar; 40(2):78-88. PubMed ID: 20113677
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
4. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
7. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
8. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
[TBL] [Abstract][Full Text] [Related]
9. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Teunissen JJ; Kwekkeboom DJ; Krenning EP
J Clin Oncol; 2004 Jul; 22(13):2724-9. PubMed ID: 15226340
[TBL] [Abstract][Full Text] [Related]
11. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
12. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
13. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ
J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894
[TBL] [Abstract][Full Text] [Related]
14. [Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
Illouz F; Sadoul JL; Rohmer V
Ann Endocrinol (Paris); 2010 Sep; 71 Suppl 1():S3-12. PubMed ID: 21237328
[TBL] [Abstract][Full Text] [Related]
15. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
Van Eijck CH
Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
[No Abstract] [Full Text] [Related]
18. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
[TBL] [Abstract][Full Text] [Related]
19. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP
Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236
[TBL] [Abstract][Full Text] [Related]
20. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]